4568 Stock Overview
Manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 4568 from our risk checks.
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Daiichi Sankyo Company, Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥4,491.00 |
| 52 Week High | JP¥6,257.00 |
| 52 Week Low | JP¥3,805.00 |
| Beta | 0.26 |
| 11 Month Change | -8.33% |
| 3 Month Change | -24.58% |
| 1 Year Change | 10.72% |
| 33 Year Change | 47.97% |
| 5 Year Change | 94.00% |
| Change since IPO | 481.99% |
Recent News & Updates
Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors
Nov 07
Daiichi Sankyo Company, Limited Just Recorded A 223% EPS Beat: Here's What Analysts Are Forecasting Next
Nov 04Recent updates
Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors
Nov 07Daiichi Sankyo Company, Limited Just Recorded A 223% EPS Beat: Here's What Analysts Are Forecasting Next
Nov 04Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00
Sep 22Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00
Sep 06Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 03Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00
Jul 26Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00
Jul 12Here's Why Daiichi Sankyo Company (TSE:4568) Has Caught The Eye Of Investors
May 22Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are
May 02Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Apr 27Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year
Mar 11Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00
Feb 26Shareholder Returns
| 4568 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.3% | -4.5% | -0.4% |
| 1Y | 10.7% | 8.6% | 11.4% |
Return vs Industry: 4568 exceeded the JP Pharmaceuticals industry which returned 8.6% over the past year.
Return vs Market: 4568 matched the JP Market which returned 11.4% over the past year.
Price Volatility
| 4568 volatility | |
|---|---|
| 4568 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.6% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4568 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4568's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1899 | 18,726 | Sunao Manabe | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent.
Daiichi Sankyo Company, Limited Fundamentals Summary
| 4568 fundamental statistics | |
|---|---|
| Market cap | JP¥8.51t |
| Earnings (TTM) | JP¥250.40b |
| Revenue (TTM) | JP¥1.76t |
33.9x
P/E Ratio4.8x
P/S RatioIs 4568 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4568 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.76t |
| Cost of Revenue | JP¥419.99b |
| Gross Profit | JP¥1.34t |
| Other Expenses | JP¥1.09t |
| Earnings | JP¥250.40b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | 132.45 |
| Gross Margin | 76.11% |
| Net Profit Margin | 14.24% |
| Debt/Equity Ratio | 6.3% |
How did 4568 perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield46%
Payout RatioDoes 4568 pay a reliable dividends?
See 4568 dividend history and benchmarks| Daiichi Sankyo Company dividend dates | |
|---|---|
| Ex Dividend Date | Sep 27 2024 |
| Dividend Pay Date | Dec 10 2024 |
| Days until Ex dividend | 56 days |
| Days until Dividend pay date | 18 days |
Does 4568 pay a reliable dividends?
See 4568 dividend history and benchmarks